03-Mar-2021

Generic Oncology Sterile Injectable Market Size and Share Is Projected To Reach US$ 27,543.1 Million at a 11.5% CAGR By 2027

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

The global generic oncology sterile injectables market, by product type (Chemotherapy (Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, and Others), Monoclonal Antibodies, Cytokines, and Peptide Hormones), by disease indication (Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, and Others), by distribution channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 11,496.7million in 2019 and is projected to exhibit a CAGR of 11.5% over the forecast period (2019-2027).

For more Information, Request PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/562

Manufacturers across the globe are adopting strategies, such as business expansion and collaborations, as they are looking forward to tapping into several emerging markets. For instance, in July 2017, India-based Alembic Pharmaceuticals established an oncology manufacturing facility for injectables and lyophilized products, with a production capacity of 60 million tablets and capsules, as well as nearly 20 million vials, in Gujarat. The new facility would develop oncology injectables and lyophilized products for sales in the U.S., North Africa, South Africa, the Middle East, and Australia, as confirmed by the company sources. In December 2016, Baxter International acquired the India-based company, Claris Injectables, for the expansion of its generic injectables product portfolio. Furthermore, in August 2017, Hikma Pharmaceuticals endeavored to extend its manufacturing capacity by 70 million units, exclusively for oncology injectables.

In October 2014, Sagent Pharmaceuticals, Inc., acquired Omega Laboratories Limited, in a bid to expand its product portfolio of generic injectables and hence, to reinforce its global presence. Furthermore, Eli Lilly & Company received the intellectual property rights for the vitamin regimen for Alimta (pemetrexed for injection) from the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (PTO) in October 2017. These rights aided the company significantly in the development of next-generation medicines.

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/562

Key Market Takeaways:

Introduction of more and more generic oncology sterile injectables into the global market acts as a major growth driver.
On the basis of disease indication, the ovarian cancer segment is expected to account for a major revenue share by 2027, owing to increasing incidence of ovarian cancer worldwide. According to the National Cancer Institute, up to 22,530 new cases of ovarian cancer were registered in the U.S. in 2019.
The leading companies operating in the global generic oncology sterile injectables market include Eli Lilly & Company, Biocon Ltd., Baxter International Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and Pfizer Inc.

Table of Contents

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Overview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snippet, By Product Type
  - Market Snippet, By Disease Indication
  - Market Snippet, By Distribution Channel
  - Market Snippet, By Region
- Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
  - Drivers
  - Restraints
  - Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Industry Trend
- Merger and Acquisitions
- New Product Approvals/Launch
- Promotion and Marketing Initiatives
- PEST Analysis
Global Generic Oncology Sterile Injectable Market, By Product Type, 2016 – 2027, (US$ Million)
- Introduction
  - Market Share Analysis, 2019 and 2027 (%)
  - Y-o-Y Growth Analysis, 2017 – 2027
  - Segment Trends
- Chemotherapy
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    - Alkylating agents
      - Introduction
      - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    - Antimetabolites
      - Introduction
      - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    - Plant Alkaloids
      - Introduction
      - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    - Antitumor Antibiotics
      - Introduction
      - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    - Others
      - Introduction
      - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Monoclonal Antibodies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Cytokines
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Peptide Hormones
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
Global Generic Oncology Sterile Injectable Market, By Disease Indication, 2016– 2027, (US$ Million)
- Introduction
  - Market Share Analysis, 2019 and 2027 (%)
  - Y-o-Y Growth Analysis, 2017 – 2027
  - Segment Trends
- Ovarian Cancer
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Breast Cancer
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Lung Cancer
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Pancreatic Cancer
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Others
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
Global Generic Oncology Sterile Injectable Market, By Distribution Channel, 2019 – 2027, (US$ Million)
- Introduction
  - Market Share Analysis, 2019 and 2027 (%)
  - Y-o-Y Growth Analysis, 2017 – 2027
  - Segment Trends
- Hospital Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Retail Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Online Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
Global Generic Oncology Sterile Injectable Market, By Region, 2019 – 2027, (US$ Million)
- Introduction
  - Market Share Analysis, By Region, 2019 and 2027 (%)
  - Y-o-Y Growth Analysis, By Region, 2017 – 2026
  - Regional Trends
- North America
  - Market Size and Forecast, By Product Type, 2016 – 2027 , (US$ Million)
  - Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
    - U.S.
    - Canada
- Europe
  - Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
    - U.K.
    - Germany
    - Italy
    - France
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
    - China
    - Japan
    - India
    - ASEAN
    - Australia
    - South Korea
    - Rest of Asia Pacific
- Latin America
  - Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Middle East
  - Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
    - GCC Countries
    - Israel
    - Rest of Middle East
- Africa
  - Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
  - Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
    - North Africa
    - Central Africa
    - South Africa
Competitive Landscape
- Company Profiles
  - Eli Lilly & Company.*
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
  - Biocon Ltd
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
  - Baxter International Inc.
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
  - Hikma Pharmaceuticals PLC
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
  - Mylan N.V.
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
  - Sandoz International GmbH
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
  - Teva Pharmaceutical Industries Ltd
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
  - Pfizer Inc.
    - Company Overview
    - Product Portfolio
    - Financial Performance
    - Recent Highlights
    - Strategies
- Analyst Views
Section
- References
- Research Methodology
- About Us and Sales Contact

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/generic-oncology-sterile-injectables-market-to-surpass-us-2340-billion-threshold-by-2025-893

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Editor Details

Company:
- CDN Newswire

Last Updated: 03-Mar-2021